A Hims alternative for medical weight loss used to be easy to argue for because the compounded GLP-1 question settled most conversations on its own. That argument is weaker now. Hims partnered with Novo Nordisk in 2026 and began selling branded Wegovy through its platform, so the safety gap between the two companies' medication supply has narrowed. The question that remains is sharper: who is reading your labs and who profits when your dose goes up?
We write this as a competitor and we will be honest about what that means. Hims is a legitimate platform selling real medication. We think the structural difference between what they do and what we do matters more than any single drug price and we will lay the math out for you to check.
- Hims partnered with Novo Nordisk in 2026 and now sells branded Wegovy, reportedly bundled at around $599 per month.
- The compound-safety critique is less decisive than it was. The sharper question is who reads your labs and who profits from dose escalation.
- GoodLife Health charges a flat $299 per month for the doctor and the quarterly Biomarker Audit, with medication billed separately by the pharmacy at cost and zero markup.
- Two separate charges mean our income never depends on which drug you take or what dose you end up on.
What Hims actually offers now
In 2026 Hims and Novo Nordisk announced a collaboration to bring branded Wegovy (and later Ozempic) to the Hims platform at cash-pay prices. Reported bundle pricing for Wegovy through Hims runs around $599 per month. Hims also continues to offer oral weight-loss medications and other products in its catalog and it discontinued advertising compounded semaglutide after the FDA warned about the risks of compounded copies.
We do not claim Hims is careless. We claim the model is different from ours in ways worth checking before you commit a year to either.
The structural differences, named plainly
| Question | Hims (typical telehealth model) | GoodLife Health |
|---|---|---|
| Who reads your labs? | Screening labs for eligibility, then prescription | Full quarterly Biomarker Audit (ApoB, Lp(a), hs-CRP, HbA1c, lipids, insulin, hormones, thyroid) read by your physician every 90 days |
| What does the fee buy? | Platform access and prescription fulfillment | The doctor, the protocols and the ongoing clinical relationship |
| How is medication priced? | Bundled subscription price | Billed by the pharmacy at cost, zero markup, no molecule upcharge, no dose-escalation fee |
| What happens at dose escalation? | The subscription price may change | Nothing changes. The fee is flat. |
The third row is the one worth reading twice. On a bundled subscription, the platform's margin depends on the gap between what you pay and what the drug costs. On our model, the pharmacy bills you at cost and the fee never moves. We make money when you get healthier, not when your dose gets stronger.
A real objection, named plainly: '$299 a month just for a doctor, plus the drug, sounds more expensive than $599 all in.' Here is the math without spin. On a $599 bundle you are paying roughly $7,188 a year with no Biomarker Audit, no quarterly labs and a clinical relationship that is mostly asynchronous messaging. On our model you pay $3,588 a year for the clinical membership ($598 for the first two months, then ten months at $299), plus the actual pharmacy cost of the medication, which you see directly with no markup added by us. Whether the total is lower depends on which drug and dose you need. What is never in question is that we have no financial stake in that answer.
What a real clinical relationship adds
Hims assigns you a licensed provider who reviews your intake and prescribes. That is a legitimate service. What it is not is a physician who has read your ApoB, your Lp(a), your hs-CRP, your thyroid panel and your hormone panel and will read them again in 90 days to see what changed.
That is not a small difference. The patients who come to us from other telehealth platforms usually arrive for one of two reasons: a dose that kept climbing with a bill that climbed with it or a plateau that nobody investigated because nobody was watching the labs.
Who should actually consider Hims
We will say this plainly because it is true. If you know exactly which drug and dose you need, you have current labs from another clinician and you want a straightforward cash-pay subscription with a predictable monthly number, Hims does that job well. We are not the right choice for everyone and a model that pretends otherwise is not honest.
We are the better fit when any of the following describes you:
- You want a physician reading your full biomarker panel every 90 days, not screening your eligibility once.
- You have been on a GLP-1 elsewhere and hit a plateau nobody explained.
- You are done with dose-escalation repricing and want a flat fee that never changes with the prescription.
- You want branded FDA-approved medication only, never compounded and you want that stated as a hard rule rather than a policy page.
Frequently asked questions
Does Hims still sell compounded semaglutide?
Hims stopped advertising compounded semaglutide after the FDA warned about the risks of compounded GLP-1 copies and after its 2026 collaboration with Novo Nordisk, which brought branded Wegovy to the platform. In limited cases compounded medication may still be available through the platform, so if avoiding compounded medication entirely matters to you, confirm which product you are actually being sold before you check out. We prescribe branded FDA-approved medication only: Wegovy, Zepbound, Ozempic, Mounjaro, Wegovy Tablets and Foundayo.
Is GoodLife Health cheaper than Hims?
For the clinical membership, yes: $299 per month (two-month $598 start, then month to month) versus a reported Wegovy bundle around $599 per month. For the all-in monthly total, it depends on which drug and dose you need, because we pass pharmacy cost through at zero markup instead of bundling. What we can promise is that the membership never changes with the dose and the medication is billed to you at exactly what the pharmacy charges.
Do I need to switch doctors to switch platforms?
No. Records transfer, labs are already on file with the ordering lab and the transition is administrative rather than clinical. We handle the intake, repeat the Biomarker Audit at the next quarterly cycle and take the protocol forward from there.
Will you keep me on my current dose?
Only if the labs and your symptoms support it. We titrate to the least medicine that gets you the most result and we have no financial reason to escalate. If your current dose is doing its job, we keep it. If a lower dose would achieve the same biomarker outcome, we lower it and tell you why.
What if I want to just pay for the medication without a membership?
That is not our model. Every prescription flows from a clinical relationship with quarterly labs, because prescribing a GLP-1 without monitoring is the exact failure mode our practice exists to fix. If you want medication alone without clinical oversight, several platforms sell it and we would rather lose the sale than practice that way.
Is GoodLife Health LegitScript certified?
Yes. Our clinical protocols are LegitScript certified and the physicians delivering care are licensed in all 50 states. Care is delivered by licensed physicians of Beluga Health, P.A., an independent professional corporation, working under GoodLife Health's clinical protocols.
Who should pick Hims instead?
If you already know your drug and dose, have recent labs and want a simple cash-pay subscription with a predictable monthly bundle, Hims does that job well. We are the better fit when you want a physician reading the full biomarker panel quarterly or when you are done with dose-escalation pricing and want a flat fee that never changes.
Related guides
- Ro alternatives: what to compare in 2026
- Cardiometabolic Optimization: the definitive guide
- How GLP-1s work and what happens when they stop
- Our flat-fee model and why it never changes with your dose
External reference: reporting on the Hims and Novo Nordisk collaboration and its pricing is available from Hims' own newsroom.
References
- Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). 2022. pubmed.ncbi.nlm.nih.gov/35658024/
- Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). 2021. pubmed.ncbi.nlm.nih.gov/33567185/